Catabasis Pharmaceuticals Inc (NASDAQ:CATB) shares traded up 3% during mid-day trading on Tuesday . The stock traded as high as $6.18 and last traded at $6.28, 4,904 shares traded hands during mid-day trading. A decline of 94% from the average session volume of 78,639 shares. The stock had previously closed at $6.10.

CATB has been the subject of a number of research analyst reports. Citigroup lowered their price target on Catabasis Pharmaceuticals from $72.00 to $60.00 in a report on Friday, November 8th. ValuEngine raised Catabasis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st.

The firm’s fifty day moving average is $5.11 and its 200-day moving average is $6.23. The company has a market capitalization of $73.75 million, a P/E ratio of -1.19 and a beta of 1.76.

Catabasis Pharmaceuticals (NASDAQ:CATB) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.63) by $0.07. Sell-side analysts expect that Catabasis Pharmaceuticals Inc will post -2.41 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in the company. Oppenheimer & Co. Inc. increased its holdings in Catabasis Pharmaceuticals by 16.2% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 79,849 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 11,143 shares in the last quarter. BlackRock Inc. increased its holdings in Catabasis Pharmaceuticals by 186.8% in the second quarter. BlackRock Inc. now owns 172,679 shares of the biotechnology company’s stock valued at $1,393,000 after purchasing an additional 112,465 shares during the period. Vanguard Group Inc. raised its position in Catabasis Pharmaceuticals by 16.0% during the 2nd quarter. Vanguard Group Inc. now owns 414,748 shares of the biotechnology company’s stock worth $3,347,000 after purchasing an additional 57,155 shares during the last quarter. Northern Trust Corp lifted its holdings in Catabasis Pharmaceuticals by 74.7% during the 2nd quarter. Northern Trust Corp now owns 50,193 shares of the biotechnology company’s stock worth $405,000 after buying an additional 21,458 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Catabasis Pharmaceuticals by 321.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 43,406 shares of the biotechnology company’s stock valued at $339,000 after buying an additional 33,106 shares during the last quarter. Institutional investors own 37.51% of the company’s stock.

About Catabasis Pharmaceuticals (NASDAQ:CATB)

Catabasis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD).

Recommended Story: What is the Current Ratio?

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.